The global vitamin market remains quiet entering early 2025, with prices mostly stable or slightly weak. Most buyers have already contracted for Q1 and part of Q2, resulting in limited new demand despite some suppliers’ attempts to firm up prices.
This summary provides an overview of recent developments in key vitamin segments, highlighting prevailing market dynamics and supplier strategies.
In partnership with Feed Additive Prices
Vitamin E 50%
No significant changes over the past few weeks. Several suppliers have a strong desire to increase prices or at least maintain stability, and some are not even willing to offer anything at this time. So far, the supply and demand balance does not seem to support a firmer market, but prices are currently also not going down. Q1 and a decent portion of Q2 have been contracted, and therefore, there is very limited activity seen.
Vitamin A 1000
Prices are mostly stable, but in some cases and/or regions, there is still a slightly weak tone to it, despite the already very low prices. There is no real new demand seen right now, as Q1 and a portion of Q2 have been contracted already. Some sellers who still have some old stock/position are therefore willing to move small volumes with a discount. But the main suppliers are not discounting prices any further, some of them do not even offer at all.
Vitamin D3 500
Prices continue to decline slowly in most regions. New demand is slow, as there is already some Q1 cover based on contracts concluded earlier in Q4 2025. And as prices are relatively high still, buyers have become very cautious not to buy too much. Quiet and weak market with only some occasional spot business seen right now.
Vitamin B2 80%
This continues to be a very static market, and prices are stable in all regions. No significant additional capacity is expected, apart from newly approved Chinese sources in Europe, which are expected in 2026. But no significant increase in demand is expected next year. Q1 is mostly contracted, and it is quiet at the moment.
D-Calpan
No changes reported, really. The market seems to have sufficient product, and prices are low. Q1 is mostly contracted, and buyers are not in a hurry to book large long positions, and suppliers continue to offer competitive prices it seems.
Vitamin B3
It seems that some suppliers are trying to move away from the very low prices and have either stopped offering or have increased their prices for new business. But that does not apply yet to all suppliers or all regions. So the market is a mix of different views and prices, although those prices are still within a small bandwidth and low-priced. Q1 is mostly contracted and a good portion of Q2 as well.
Biotin
Prices have remained consistently low for an extended period, showing no significant shifts in supply and demand or market dynamics in the near future. The contracts for the first quarter and a substantial part of the second quarter are already in place.
Vitamin C 35% mono
Late Q4 2025, there was a slightly firmer market seen for several vitamin C products, as suppliers were starting to offer significant resistance against selling at the current low price level. But that did not seem to trigger any significant new buying, and currently the market is stable again and calm. Q1 is contracted, and a good portion of Q2 is as well.
